{"id":"tavaborole-5-topical-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":{"setId":"050f5d10-5591-426e-9020-6516b3363304","title":"TAVABOROLE (TAVABOROLE TOPICAL SOLUTION, 5%) SOLUTION [ENCUBE ETHICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tavaborole is a benzoxaborole antifungal that selectively inhibits squalene epoxidase, a key enzyme in the fungal ergosterol biosynthesis pathway. By blocking ergosterol production, the drug compromises fungal cell membrane integrity, leading to cell death. This mechanism is selective for fungal cells and has activity against dermatophytes and other fungi causing onychomycosis.","oneSentence":"Tavaborole inhibits fungal squalene epoxidase, disrupting ergosterol synthesis and causing fungal cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:19.984Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Onychomycosis (fungal nail infection) caused by dermatophytes"}]},"trialDetails":[{"nctId":"NCT01302119","phase":"PHASE3","title":"Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02","conditions":"Onychomycosis of Toenails","enrollment":604},{"nctId":"NCT01270971","phase":"PHASE3","title":"Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12-01","conditions":"Onychomycosis of Toenails","enrollment":594},{"nctId":"NCT03405818","phase":"PHASE4","title":"An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-10-22","conditions":"Onychomycosis, Tinea Unguium","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kerydin"],"phase":"marketed","status":"active","brandName":"Tavaborole 5% Topical Solution","genericName":"Tavaborole 5% Topical Solution","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tavaborole 5% Topical Solution is a small molecule inhibitor of leucine-tRNA ligase, used to treat onychomycosis of the toenail, onychomycosis, and tinea unguium. It is a leucine-tRNA ligase inhibitor that has been evaluated in clinical trials for its efficacy and safety in treating these conditions.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-07-07T00:00:00.000Z","mah":"ANACOR PHARMS INC","brand_name_local":"KERYDIN","application_number":"NDA204427"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}